Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept Study.

Background: Smartphones and wearables are revolutionizing the assessment of cognitive and motor function in neurological disorders, allowing for objective, frequent, and remote data collection. However, these assessments typically provide a plethora of sensor-derived measures (SDMs), and selecting the most suitable measure for a given context of use is a challenging, often overlooked problem.

Objective: This analysis aims to develop and apply an SDM selection framework, including automated data quality checks and the evaluation of statistical properties, to identify robust SDMs that describe the cognitive and motor function of people with multiple sclerosis (MS).

Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.

Background: The Konectom™ smartphone-based cognitive processing speed (CPS) test is designed to assess processing speed and account for impact of visuomotor function on performance.

Objective: Evaluate reliability and validity of Konectom CPS Test, performed in clinic and remotely.

Methods: Data were collected from people with multiple sclerosis (PwMS) aged 18-64 years and healthy control participants (HC) matched for age, sex, and education.

Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.

Background: Biomarkers are known to predict major adverse cardiovascular events. However, the association of biomarkers with complex coronary revascularization procedures or high-risk coronary anatomy at the time of revascularization is not understood.

Objectives: We examined the associations between baseline biomarkers and major coronary events (MCE) and complex revascularization procedures.

Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.

Background: Patients with prior percutaneous coronary intervention (PCI) are at high residual risk for multiple types of coronary events within and beyond the stented lesion. This risk might be mitigated by more intensive LDL-C (low-density lipoprotein cholesterol)-lowering beyond just with statin therapy.

Methods: FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) randomized 27 564 patients with stable atherosclerotic disease on statin to the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab or placebo with a median follow-up of 2.

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.

Aims: We assessed the impact of the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab on acute arterial events across all vascular territories, including coronary, cerebrovascular, and peripheral vascular beds, in patients with established atherosclerotic cardiovascular disease (ASCVD).

Methods And Results: In the FOURIER trial, 27 564 patients with stable ASCVD on statin therapy were randomly assigned to evolocumab or placebo. Acute arterial events were a composite of acute coronary (coronary heart disease death, myocardial infarction, or urgent coronary revascularization), cerebrovascular (ischaemic stroke, transient ischaemic attack, or urgent cerebral revascularization), or peripheral vascular (acute limb ischaemia, major amputation, or urgent peripheral revascularization) events.

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.

Background: There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial, which randomized stable atherosclerosis patients to receive either evolocumab or placebo.

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.

Aims: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding.

Methods And Results: ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months.

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.

Objectives: This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization.

Background: PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall.

Methods: FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) was a randomized trial of the PCSK9 inhibitor evolocumab versus placebo in 27,564 patients with stable atherosclerotic cardiovascular disease on statin therapy followed for a median of 2.

Injuries among solid waste collectors in the private versus public sectors.

Solid waste collection is among the occupations with the highest risk for injuries and illnesses. Solid waste collector injuries were characterized in terms of injury risk and employment industry sector (public versus private) using Kentucky workers' compensation first reports of injury and claims data. When compared to 35-44-year-old workers, solid waste collectors who were under 35 years of age were less likely to have a workers' compensation first report of injury or claim that resulted in awarded benefits.

Synthesis and characterization of di- and trivalent pyrazolylborate β-diketonates and cyanometalates.

The syntheses, structures, and magnetic properties of a series of di- and trivalent hydridotris(3,5-dimethylpyrazol-1-yl)borate (Tp*) cyanomanganates are described. Treatment of tris(acetylacetonate)manganese(III) [Mn(acac)(3)] with KTp* and tetra(ethyl)ammonium cyanide affords [NEt(4)][(Tp*)Mn(II)(κ(2)-acac)(CN)] (1), as the first monocyanomanganate(II) complex; attempted oxidation of 1 with iodine affords {(Tp*)Mn(II)(κ(2)-acac(3-CN))}(n) (2) as a one-dimensional chain and bimetallic {[NEt(4)][(Tp*)Mn(II)(κ(2)-acac(3-CN))](2)(μ-CN) (3) as the major and minor products, respectively. A fourth complex, [NEt(4)][(Tp*)Mn(II)(η(2)-acac(3-CN))(η(1)-NC-acac)] (4), is obtained via treatment of Mn(acac(3-CN))(3) with KTp* and [NEt(4)]CN, while [NEt(4)](2)[Mn(II)(CN)(4)] (5) was prepared from manganese(II) trifluoromethanesulfonate and excess [NEt(4)]CN.

First structurally characterized tricyanomanganate(III) and its magnetic {Mn(III)(2)M(II)(2)} complexes (M(II) = Mn, Ni).

Treatment of tris(3-cyano-2,4-pentanedionato)manganese(III) with KTp*, followed by [NEt(4)]CN affords [NEt(4)][(Tp*)Mn(III)(CN)(3)] (1); subsequent treatment of 1 with divalent triflates (OTf) and 2,2'-bipyridine (bpy) affords {Mn(III)(2)M(II)(2)} complexes (M(II) = Mn, 2; Ni, 3). Magnetic measurements show that 1-3 exhibit S(T) = 1, 3, and 4 spin ground states, respectively.